Management of CKD with No Proteinuria and Normal Blood Pressure
For patients with chronic kidney disease who have no proteinuria and normal blood pressure, continue monitoring without initiating antihypertensive therapy, as ACE inhibitors or ARBs are not indicated in this population and may cause harm without providing renoprotective benefit.
Blood Pressure Target and Monitoring
Since your patient has normal blood pressure, the goal is to maintain BP <140/90 mmHg 1, 2. The lower target of <130/80 mmHg is specifically reserved for patients with proteinuria (>500 mg/24h or ACR >30 mg/mmol), which your patient does not have 1.
The 2024 ESC guidelines recommend treating CKD patients when office BP reaches ≥140/90 mmHg, targeting a systolic BP range of 130-139 mmHg 3. For patients with moderate-to-severe CKD (eGFR >30 mL/min/1.73 m²), a lower target of 120-129 mmHg may be considered if tolerated, but this is based on the SPRINT trial which included patients with and without proteinuria 3.
Medication Considerations
Do not initiate ACE inhibitors or ARBs in your patient. The evidence is clear on this point:
- ACE inhibitors and ARBs are indicated as first-line therapy only for CKD patients with proteinuria (urinary protein >500 mg/24h or ACR >30 mg/mmol) 1, 4
- For non-proteinuric CKD, these agents lack demonstrated renoprotective efficacy 5, 6
- The combination of ACE inhibitor and ARB is explicitly not recommended for patients with nonproteinuric CKD 1, 4
The rationale is straightforward: the nephroprotective benefits of RAS blockade are primarily seen in proteinuric kidney disease. Extended follow-up studies demonstrate that intensive BP control reduces kidney failure risk in patients with proteinuria but not in those without 7.
If Blood Pressure Becomes Elevated
Should your patient develop hypertension (BP ≥140/90 mmHg), appropriate first-line agents include:
- Thiazide or thiazide-like diuretics
- Long-acting calcium channel blockers (dihydropyridines)
- ACE inhibitors or ARBs (though less preferential without proteinuria)
Multiple agents are often needed to achieve target BP 1. Thiazide diuretics are specifically recommended as additive therapy in CKD 1, 4. For patients with volume overload, loop diuretics are an alternative 1, 4.
Monitoring Strategy
Regular monitoring should include:
- Blood pressure checks at routine intervals using standardized office measurement
- Urinalysis for proteinuria at least annually, as development of proteinuria would change management strategy
- Serum creatinine and eGFR to track kidney function
- Electrolytes if medications are initiated
Critical Pitfall to Avoid
The most common error is reflexively starting an ACE inhibitor or ARB simply because a patient has CKD. This is inappropriate without proteinuria 1, 4. These medications can cause acute kidney injury, hyperkalemia, and hypotension without providing the renoprotective benefits seen in proteinuric disease 1, 5.
Lifestyle Modifications
Regardless of medication status, emphasize:
- Sodium restriction to <2.0 g/day (<90 mmol/day) 8
- Weight normalization if overweight
- Smoking cessation
- Regular exercise
These interventions are synergistic for BP control and kidney protection 8.
When to Reassess
Reevaluate management if:
- BP rises to ≥140/90 mmHg on repeated measurements
- Proteinuria develops (ACR ≥30 mg/mmol or protein ≥500 mg/24h)
- eGFR declines significantly
- Cardiovascular disease develops
Development of proteinuria would shift the treatment paradigm to favor ACE inhibitor or ARB therapy as first-line 1, 9, 2.